DXCM Stock Risk & Deep Value Analysis
Dexcom Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About DXCM Stock
We analyzed Dexcom Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DXCM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
DXCM Risk Analysis & Red Flags
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium-High
Execution
Medium
Regulatory
Low-Medium
Upcoming Risk Events
- 📅
Increased competitive pressure from Abbott (Freestyle Libre) and Medtronic
- 📅
Slower-than-expected adoption of G7 or Stelo
- 📅
Regulatory challenges or changes impacting product approvals or reimbursement
- 📅
Supply chain disruptions impacting manufacturing or distribution
Unlock DXCM Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Dexcom Inc (DXCM) Do?
Market Cap
$26.21B
Sector
Healthcare
Industry
Medical Devices
Employees
10,200
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Visit Dexcom Inc WebsiteInvestment Thesis
Dexcom is a high-quality, fundamentally sound market leader in the growing CGM space, poised to expand its Total Addressable Market significantly through G7 adoption and penetration into the Type 2 non-insulin market with Stelo. Its strong financials, consistent execution, and leadership position make it a compelling long-term growth investment in healthcare, albeit with limited 10x potential from its current large-cap valuation.
Is DXCM Stock Undervalued?
Unlock the full AI analysis for DXCM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
DXCM Price Targets & Strategy
12-Month Target
$85.00
Bull Case
$110.00
Bear Case
$65.00
Valuation Basis
Based on 28x forward P/E applied to est. FY26 EPS of $3.03
Entry Strategy
Dollar-cost average between $60-$65, targeting dips towards historical support levels.
Exit Strategy
Consider profit-taking 25-50% position between $85-$95. Set a stop-loss order at $60 to protect against significant downside.
Portfolio Allocation
5% for moderate risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is DXCM Financially Healthy?
Valuation
P/E Ratio
32.43
Forward P/E
22.79
EV/EBITDA
20.78
PEG Ratio
1.32
Price/Book
9.52
Price/Sales
5.40
Profitability
Gross Margin
60.10%
Operating Margin
19.56%
Net Margin
17.94%
Return on Equity
34.50%
Revenue Growth
13.10%
EPS
$2.09
Balance Sheet
Current Ratio
1.88
Quick Ratio
1.59
Debt/Equity
0.45
Total Debt
$1.40B
Cash & Equivalents
$2.00B
Cash Flow
Operating Cash Flow
$1.39B
Free Cash Flow
$1.07B
EBITDA
$1.16B
Other
Beta (Volatility)
1.48
Does DXCM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
Dexcom's moat is durable due to extensive R&D investment, patented technology, stringent regulatory hurdles for new entrants, and the high switching costs associated with patient and clinician familiarity and data integration within existing healthcare systems.
Moat Erosion Risks
- •Aggressive pricing strategies or superior next-gen technology from competitors (e.g., non-invasive glucose monitoring)
- •Regulatory changes that could streamline market entry for rivals or alter reimbursement policies
- •Dependence on continuous innovation to maintain technological edge
DXCM Competitive Moat Analysis
Sign up to see competitive advantages
DXCM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data provided, but generally positive given company standing)
Institutional Sentiment
Positive (97.75% institutional ownership; Citigroup upgraded price target from $77 to $84 on March 11, 2026)
Insider Activity (Form 4)
No specific Form 4 filings detailed for Dec 23, 2025–Mar 23, 2026.
Options Flow
Normal options activity
Earnings Intelligence
Next Earnings
2026-04-23
Surprise Probability
Medium
Historical Earnings Pattern
Generally positive reaction to earnings beats, with stock often showing modest gains; guidance is a key driver for post-earnings movement.
Key Metrics to Watch
Competitive Position
Top Competitor
ABT
Market Share Trend
Stable but under pressure (Barclays notes rising competitive pressure, but DXCM continues strong G7 and Stelo rollouts suggesting continued leadership).
Valuation vs Peers
Trading at a reasonable premium to some medical device peers on a forward P/E basis (22.79) given its growth trajectory and market leadership, but not significantly overvalued based on PEG (1.34).
Competitive Advantages
- •Proprietary R&D and deep regulatory expertise
- •Strong brand recognition and established physician/patient trust
- •Continuous product innovation (G7, Stelo) and pipeline development
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive DXCM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on 2026-04-23
- •Continued global rollout and adoption of G7 CGM system
- •Further market penetration and traction for Stelo in Type 2 non-insulin market
Medium-Term (6-18 months)
- •Expansion into new international markets for G7 and Stelo
- •Strategic partnerships for device integration or data solutions
- •Potential new product pipeline announcements or regulatory approvals beyond current offerings
Long-Term (18+ months)
- •Dominance in a fully integrated, automated diabetes management ecosystem
- •Leveraging AI and data analytics for personalized health insights
- •Evolution of CGM technology (e.g., implantable, longer-wear sensors)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for DXCM?
- ✓
Acceleration in Stelo adoption rates and Type 2 market penetration
- ✓
Sustained double-digit organic revenue growth (above 15% YoY)
- ✓
Evidence of expanding gross and operating margins, indicating pricing power and scale efficiency
- ✓
Competitive responses and market share trends against key rivals
Bull Case Analysis
See what could go right with Premium
Competing with DXCM
See how Dexcom Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Dexcom Inc DXCM | $26.2B | 6.6 | 32.4 | $4.7B | 17.9% | 13.1% | |
Abbott Laboratories ABT | $182.2B | 2.2 | 28.3 | $44.3B | 14.7% | 4.4% | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Dexcom Inc (DXCM)?
As of March 23, 2026, Dexcom Inc has a DVR Score of 6.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Dexcom Inc?
Dexcom Inc's market capitalization is approximately $26.2B. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Dexcom Inc use?
DXCM is the ticker symbol for Dexcom Inc. The company trades on the NMS.
What is the risk level for DXCM stock?
Our analysis rates Dexcom Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of DXCM?
Dexcom Inc currently has a price-to-earnings (P/E) ratio of 32.4. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Dexcom Inc's revenue growing?
Dexcom Inc has reported revenue growth of 13.1%. The company is showing strong top-line momentum.
Is DXCM stock profitable?
Dexcom Inc has a profit margin of 17.9%. The company is profitable but margins are modest.
How often is the DXCM DVR analysis updated?
Our AI-powered analysis of Dexcom Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for DXCM (Dexcom Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.